DXNVX Enters Main Track and Accelerates Development of Oral Obesity Treatment

DXVX, gaining attention for its innovative oral GLP-1 obesity treatment development, is accelerating the optimization of new drug candidates expected to demonstrate stronger and safer efficacy based on previous research confirming superior activity compared to control substances in late-stage clinical trials.

The oral GLP-1 (glucagon-like peptide-1) obesity treatment under development by DXVX is a hormone that suppresses appetite and increases satiety, leading to weight loss and showing excellent effects in obesity treatment.

The DXVX research team has developed organic compounds that can be taken orally once a day instead of injectable treatments, and these compounds are expected to have a lower likelihood of side effects compared to existing GLP-1 treatments.

While global pharmaceutical giants such as Lilly and other obesity treatment developers are conducting clinical trials of oral GLP-1 organic compound new drugs, the importance of the oral obesity treatment field is growing daily, especially as Pfizer has decided to resume clinical trials of its previously halted oral GLP-1 organic compound obesity treatment.

Based on AI-driven innovative drug design technology, DXVX has secured excellent candidate compounds to date and plans to submit patents for at least two or more compounds within this year.

This research achievement is receiving significant attention in the industry, with some companies exploring potential collaborations with DXVX, attracting considerable interest from many domestic and international pharmaceutical companies.

Leveraging these achievements, DXVX is expected to further accelerate the development of oral GLP-1 obesity treatments by utilizing various options such as early licensing out, global joint clinical trials, and research funding investments. With additional research results and patent applications forthcoming, the obesity treatments under development by DXVX are anticipated to gain even stronger market competitiveness in the future.

A DXVX representative stated, "The current research outcomes and development progress are important achievements that demonstrate the potential of an oral obesity treatment combining safety and strong efficacy required by the market. We will continue to devote our best efforts to early commercialization of innovative treatments through ongoing research and development and present these results at international conferences and other venues."